Cyclin A Is a Proliferative Marker with Good Prognostic Value in Node-Negative Breast Cancer.

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

Standard

Cyclin A Is a Proliferative Marker with Good Prognostic Value in Node-Negative Breast Cancer. / Ahlin, Cecilia; Zhou, Wenjing; Holmqvist, Marit; Holmberg, Lars; Nilsson, Cecilia; Jirström, Karin; Blomqvist, Carl; Amini, Rose-Marie; Fjällskog, Marie-Louise.

I: Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, Vol. 18, 2009, s. 2501-2506.

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

Harvard

APA

CBE

MLA

Vancouver

Author

Ahlin, Cecilia ; Zhou, Wenjing ; Holmqvist, Marit ; Holmberg, Lars ; Nilsson, Cecilia ; Jirström, Karin ; Blomqvist, Carl ; Amini, Rose-Marie ; Fjällskog, Marie-Louise. / Cyclin A Is a Proliferative Marker with Good Prognostic Value in Node-Negative Breast Cancer. I: Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2009 ; Vol. 18. s. 2501-2506.

RIS

TY - JOUR

T1 - Cyclin A Is a Proliferative Marker with Good Prognostic Value in Node-Negative Breast Cancer.

AU - Ahlin, Cecilia

AU - Zhou, Wenjing

AU - Holmqvist, Marit

AU - Holmberg, Lars

AU - Nilsson, Cecilia

AU - Jirström, Karin

AU - Blomqvist, Carl

AU - Amini, Rose-Marie

AU - Fjällskog, Marie-Louise

N1 - The information about affiliations in this record was updated in December 2015. The record was previously connected to the following departments: Faculty of Medicine (000022000), Paediatrics (Lund) (013002000), Pathology, (Lund) (013030000), Paediatric Hematologic Research Group (013243020)

PY - 2009

Y1 - 2009

N2 - BACKGROUND: Proliferative markers are not recommended as prognostic factors for clinical use in breast cancer due to lack of standardization in methodology. However, proliferation is driving several gene expression signatures emphasizing the need for a reliable proliferative marker for clinical use. Studies suggest that cyclin A is a prognostic marker with satisfying reproducibility. We investigated cyclin A as a prognostic marker in node-negative breast cancer using previously defined cutoff values. Patients and METHODS: In a case-control study, we defined 190 women who died from breast cancer as cases and 190 women alive at the time for the corresponding case's death as controls. Inclusion criteria were tumor size </=50 mm, no lymph node metastases and no adjuvant chemotherapy. Tumor tissues were immunostained for cyclin A using commercially available antibodies. RESULTS: We found a statistically significant association between expression of cyclin A and breast cancer death in a univariate model: odds ratio for cyclin A(ave) 2.7 [95% confidence interval (CI), 1.7-4.3] and cyclin A(max) 3.4 (CI, 2.1-5.5). Corresponding odds ratio for Ki67 were Ki67(ave) 1.9 (CI, 1.2-3.1) and Ki67(max) 1.7 (CI, 1.1-2.7) and for grade 3.1 (CI, 1.8-5.1). Cyclin A was strongly correlated to Ki67 and grade why a model including all was not appropriate. CONCLUSIONS: Cyclin A is a prognostic factor for breast cancer death in node-negative patients using standardized methodology regarding scoring and cutoff values. Adding cyclin A as a proliferative marker to established clinicopathologic factors will improve the separation of low and high risk breast cancer. (Cancer Epidemiol Biomarkers Prev 2009;18(9):2501-6).

AB - BACKGROUND: Proliferative markers are not recommended as prognostic factors for clinical use in breast cancer due to lack of standardization in methodology. However, proliferation is driving several gene expression signatures emphasizing the need for a reliable proliferative marker for clinical use. Studies suggest that cyclin A is a prognostic marker with satisfying reproducibility. We investigated cyclin A as a prognostic marker in node-negative breast cancer using previously defined cutoff values. Patients and METHODS: In a case-control study, we defined 190 women who died from breast cancer as cases and 190 women alive at the time for the corresponding case's death as controls. Inclusion criteria were tumor size </=50 mm, no lymph node metastases and no adjuvant chemotherapy. Tumor tissues were immunostained for cyclin A using commercially available antibodies. RESULTS: We found a statistically significant association between expression of cyclin A and breast cancer death in a univariate model: odds ratio for cyclin A(ave) 2.7 [95% confidence interval (CI), 1.7-4.3] and cyclin A(max) 3.4 (CI, 2.1-5.5). Corresponding odds ratio for Ki67 were Ki67(ave) 1.9 (CI, 1.2-3.1) and Ki67(max) 1.7 (CI, 1.1-2.7) and for grade 3.1 (CI, 1.8-5.1). Cyclin A was strongly correlated to Ki67 and grade why a model including all was not appropriate. CONCLUSIONS: Cyclin A is a prognostic factor for breast cancer death in node-negative patients using standardized methodology regarding scoring and cutoff values. Adding cyclin A as a proliferative marker to established clinicopathologic factors will improve the separation of low and high risk breast cancer. (Cancer Epidemiol Biomarkers Prev 2009;18(9):2501-6).

U2 - 10.1158/1055-9965.EPI-09-0169

DO - 10.1158/1055-9965.EPI-09-0169

M3 - Article

VL - 18

SP - 2501

EP - 2506

JO - Cancer Epidemiology Biomarkers and Prevention

JF - Cancer Epidemiology Biomarkers and Prevention

SN - 1538-7755

ER -